Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 3
2005 1
2006 3
2007 5
2008 11
2009 9
2010 4
2011 14
2012 21
2013 23
2014 27
2015 30
2016 30
2017 26
2018 40
2019 32
2020 34
2021 45
2022 35
2023 44
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

381 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Introduction.
Kanetsuna Y, Maruyama S. Kanetsuna Y, et al. Among authors: maruyama s. Nephron. 2023;147 Suppl 1:5. doi: 10.1159/000533694. Epub 2023 Aug 23. Nephron. 2023. PMID: 37611555 Free article. No abstract available.
Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.
Writing Group for the CKD Prognosis Consortium; Grams ME, Coresh J, Matsushita K, Ballew SH, Sang Y, Surapaneni A, Alencar de Pinho N, Anderson A, Appel LJ, Ärnlöv J, Azizi F, Bansal N, Bell S, Bilo HJG, Brunskill NJ, Carrero JJ, Chadban S, Chalmers J, Chen J, Ciemins E, Cirillo M, Ebert N, Evans M, Ferreiro A, Fu EL, Fukagawa M, Green JA, Gutierrez OM, Herrington WG, Hwang SJ, Inker LA, Iseki K, Jafar T, Jassal SK, Jha V, Kadota A, Katz R, Köttgen A, Konta T, Kronenberg F, Lee BJ, Lees J, Levin A, Looker HC, Major R, Melzer Cohen C, Mieno M, Miyazaki M, Moranne O, Muraki I, Naimark D, Nitsch D, Oh W, Pena M, Purnell TS, Sabanayagam C, Satoh M, Sawhney S, Schaeffner E, Schöttker B, Shen JI, Shlipak MG, Sinha S, Stengel B, Sumida K, Tonelli M, Valdivielso JM, van Zuilen AD, Visseren FLJ, Wang AY, Wen CP, Wheeler DC, Yatsuya H, Yamagata K, Yang JW, Young A, Zhang H, Zhang L, Levey AS, Gansevoort RT. Writing Group for the CKD Prognosis Consortium, et al. JAMA. 2023 Oct 3;330(13):1266-1277. doi: 10.1001/jama.2023.17002. JAMA. 2023. PMID: 37787795 Free PMC article.
Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.
Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T; PREDICT Investigators. Hayashi T, et al. Among authors: maruyama s. Clin J Am Soc Nephrol. 2020 May 7;15(5):608-615. doi: 10.2215/CJN.08900719. Epub 2020 Apr 3. Clin J Am Soc Nephrol. 2020. PMID: 32245781 Free PMC article. Clinical Trial.
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators. Kimura K, et al. Among authors: maruyama s. Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1. Am J Kidney Dis. 2018. PMID: 30177485 Free article. Clinical Trial.
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.
Nagasu H, Yano Y, Kanegae H, Heerspink HJL, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Tani Y, Wada J, Sugiyama H, Tsuruya K, Nakano T, Maruyama S, Wada T, Yamagata K, Narita I, Tamura K, Yanagita M, Terada Y, Shigematsu T, Sofue T, Ito T, Okada H, Nakashima N, Kataoka H, Ohe K, Okada M, Itano S, Nishiyama A, Kanda E, Ueki K, Kashihara N. Nagasu H, et al. Among authors: maruyama s. Diabetes Care. 2021 Nov;44(11):2542-2551. doi: 10.2337/dc21-1081. Epub 2021 Sep 30. Diabetes Care. 2021. PMID: 34593566 Free PMC article.
microRNA-induced IgA nephropathy.
Imai E, Maruyama S. Imai E, et al. Among authors: maruyama s. J Am Soc Nephrol. 2012 May;23(5):765-6. doi: 10.1681/ASN.2012030249. Epub 2012 Apr 12. J Am Soc Nephrol. 2012. PMID: 22499587 No abstract available.
Immunology of membranous nephropathy.
Akiyama S, Imai E, Maruyama S. Akiyama S, et al. Among authors: maruyama s. F1000Res. 2019 May 24;8:F1000 Faculty Rev-734. doi: 10.12688/f1000research.17589.1. eCollection 2019. F1000Res. 2019. PMID: 31168358 Free PMC article. Review.
Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).
Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, Maruyama S, Wada T, Terada Y, Yamagata K, Narita I, Yanagita M, Sugiyama H, Shigematsu T, Ito T, Tamura K, Isaka Y, Okada H, Tsuruya K, Yokoyama H, Nakashima N, Kataoka H, Ohe K, Okada M, Kashihara N. Sofue T, et al. Among authors: maruyama s. PLoS One. 2020 Jul 20;15(7):e0236132. doi: 10.1371/journal.pone.0236132. eCollection 2020. PLoS One. 2020. PMID: 32687544 Free PMC article.
381 results